株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

免疫治療薬の世界市場の予測 2021年:薬剤タイプ、治療領域、エンドユーザーおよび地域別分析

Immunotherapy Drugs Market by Type of Drugs (Adult Vaccines, Checkpoint Inhibitors, Interferons Alpha), Therapy Area (Cancer, Autoimmune Diseases, Infectious Diseases), End-User (Hospitals), Region (North America, Asia-Pacific) - Global Forecast to 2021

発行 MarketsandMarkets 商品コード 346465
出版日 ページ情報 英文 176 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.37円で換算しております。
Back to Top
免疫治療薬の世界市場の予測 2021年:薬剤タイプ、治療領域、エンドユーザーおよび地域別分析 Immunotherapy Drugs Market by Type of Drugs (Adult Vaccines, Checkpoint Inhibitors, Interferons Alpha), Therapy Area (Cancer, Autoimmune Diseases, Infectious Diseases), End-User (Hospitals), Region (North America, Asia-Pacific) - Global Forecast to 2021
出版日: 2017年01月06日 ページ情報: 英文 176 Pages
概要

当レポートでは、世界の免疫治療薬の市場について調査し、癌の発症数・死亡数・5年有病数の推計、主要国の薬価設定・償還環境、パイプラインの状況、現在の治療プロトコル・治療の選択、免疫治療薬市場の成長推進因子・阻害因子および市場機会の分析、薬剤タイプ・地域/国別の主要動向および市場規模の推移と予測、競合環境と市場シェア、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

  • 免疫治療薬市場の見通し
  • 治療領域および地域別市場
  • 地域概要
  • 薬剤タイプ別
  • ライフサイクル分析:地域別

第5章 市場概要

  • イントロダクション
    • 成長推進因子
    • 成長阻害因子
    • 市場機会
    • 課題

第6章 産業分析

  • イントロダクション
  • 疫学
    • 癌の疫学
    • 自己免疫疾患の疫学
  • 薬価設定・償還
    • 米国
    • 英国
    • フランス
    • ドイツ
    • その他の欧州諸国
    • 日本
  • 研究費および政府主導
  • パイプライン
    • 第I相
    • 第I/II相
    • 第II相
    • 第II/III相
    • 第III相
    • 申請済み
    • 確実視される分子
  • 産業動向
  • 発売予定の主な製品
  • 治療プロトコル・治療の選択
    • 第一選択療法
    • 第二選択療法
    • その他
  • 優先課題

第7章 市場分析:薬剤タイプ別

  • イントロダクション
  • モノクローナル抗体
  • 成人用ワクチン
    • 予防ワクチン
    • 治療ワクチン
  • チェックポイント阻害薬
  • インターフェロン
  • インターロイキン
  • その他

第8章 市場分析:治療領域別

  • イントロダクション
  • 自己免疫疾患・炎症性疾患
  • 感染症
  • その他

第9章 市場分析:エンドユーザー別

  • イントロダクション
  • 病院
  • クリニック
  • その他

第10章 市場分析:地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
  • アジア太平洋
    • 日本
    • 中国
    • インド
  • その他

第11章 競合環境

  • イントロダクション
  • 戦略的分析
  • 市場シェア分析
  • 競合状況・動向
    • 承認
    • 協業
    • 合意
    • 買収

第12章 企業概要(概要、製品・サービス、戦略、アナリストの分析、発展動向、MnMの見解)

  • イントロダクション
  • F. HOFFMANN-LA ROCHE AG
  • MERCK & CO., INC.
  • NOVARTIS INTERNATIONAL AG
  • JOHNSON & JOHNSON (JANSSEN BIOTECH, INC.の親会社)
  • GLAXOSMITHKLINE PLC
  • AMGEN INC.
  • ABBVIE
  • ASTRAZENECA
  • BRISTOL-MYERS SQUIBB
  • ELI LILLY AND COMPANY

第13章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PH 3926

The global immunotherapy drugs market is projected to reach USD 201.52 billion by 2021 from USD 108.41 billion in 2016, growing at a CAGR of 13.5% during the forecast period of 2016 to 2021.

In this report, the immunotherapy drugs market is segmented on the basis of type of drugs, therapy area, end user, and region. Increasing adoption of targeted therapies with fewer side effects, quicker drug approval processes, and high prevalence rate of lifestyle diseases are major growth drivers of this market. On the other hand, the high cost of immunotherapy treatment, and high attrition rate in the product development cycle are the major factors hindering the growth of the immunotherapy drugs market. However, rising opportunities in the emerging markets, and immunotherapy as an alternative to chemotherapy for first line treatment are the factors supporting the growth of immunotherapy drugs market.

Based on type of drugs, the market is segmented into monoclonal antibodies, adult vaccines, checkpoint inhibitors, interferons alpha & beta, interleukins, and others. Adult vaccines segment is further categorized into preventive vaccines and therapeutic vaccines. Monoclonal antibodies segment is expected to account for the largest market share in the immunotherapy drugs market, by type of drugs in 2016. On the other hand, checkpoint inhibitors segment is expected to be the fastest growing segment in the immunotherapy drugs market, by type of drugs, in 2016. The high growth of this segment can be attributed to factors such as increasing adoption of checkpoint inhibitors in cancer treatment with their ability to target only foreign cells leaving normal cells alone.

On the basis of therapy area, the immunotherapy drugs market is segmented into cancer, autoimmune & inflammatory diseases, infectious diseases, and others. Among these segments, the cancer segment is expected to account for the largest market share in 2016. Cancer segment is also expected to be the fastest growing segment in the immunotherapy drugs market, by therapy area in 2016. The large share and high growth of this segment can be attributed to factor such as high preference for immunotherapy as a first line of treatment in cancer leading to growing demand for immunotherapy drugs.

Based on geography, the immunotherapy drugs market is segmented into North America, Europe, Asia-Pacific, and Rest of the World. North America is expected to account for largest share in the immunotherapy drugs market, by region in 2016. Asia-Pacific is expected to be the fastest-growing regional segment in the immunotherapy drugs market. The high growth of this segment can primarily be attributed to the low cost of manufacturing and acceptable regulatory scenario in this region.

Acquisitions and new product approval was the most widely adopted growth strategy pursued by players in the immunotherapy drugs market, to increase their shares and cater to the unmet needs. The major players operating in the immunotherapy drugs market include F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline (U.K.), AbbVie, Inc. (U.S.), Amgen, Inc. (U.S.), Merck & Co., Inc. (U.S.). Bristol-Myers Squibb (U.S.), Novartis International AG (Switzerland), Eli Lilly and Company (U.S.), Johnson & Johnson (U.S.), and AstraZeneca plc (U.K.).

Research Coverage:

The report provides a picture immunotherapy drugs market across different industry verticals and regions. It aims at estimating the market size and future growth potential of this market across different segments such as type of drugs, therapy area, end user, and region. Furthermore, the report also includes an in-depth competitive analysis of the key players in the market along with their company profiles, recent developments, and key market strategies.

Reasons to Buy the Report:

This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios of the top players in the immunotherapy drugs market. The report provides an analysis of the immunotherapy drugs market, by treatment modality, application, and region
  • Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and new product launches in the immunotherapy drugs market
  • Market Development: Comprehensive information about lucrative emerging markets. This report provides an analysis of the immunotherapy drugs market across regions
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the global immunotherapy drugs market
  • Competitive Assessment: In-depth assessment of market strategies, product portfolios, and manufacturing capabilities of the leading players in the global immunotherapy drugs market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
    • 1.2.1. MARKETS COVERED
    • 1.2.2. YEARS CONSIDERED FOR THE STUDY
  • 1.3. CURRENCY
  • 1.4. LIMITATIONS
  • 1.5. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. MARKET SIZE ESTIMATION
  • 2.2. MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.3. MARKET SHARE ESTIMATION
    • 2.3.1. KEY DATA FROM SECONDARY SOURCES
    • 2.3.2. KEY DATA FROM PRIMARY SOURCES
    • 2.3.3. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

  • 3.1. INTRODUCTION
  • 3.2. CONCLUSION

4. PREMIUM INSIGHTS

  • 4.1. GLOBAL IMMUNOTHERAPY DRUGS MARKET OVERVIEW
  • 4.2. IMMUNOTHERAPY DRUGS MARKET: BY THERAPY AREA & REGION
  • 4.3. IMMUNOTHERAPY DRUGS MARKET: GEOGRAPHIC SNAPSHOT
  • 4.4. IMMUNOTHERAPY DRUGS MARKET, BY TYPE OF DRUG
  • 4.5. LIFE CYCLE ANALYSIS, BY REGION (2016)

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
    • 5.1.1. DRIVERS
      • 5.1.1.1. Increasing Adoption of Targeted Therapy Over Traditional Therapy
      • 5.1.1.2. Emergence of Biosimilars
      • 5.1.1.3. Increasing Demand for mAbs
      • 5.1.1.4. High Prevalence Rate of Lifestyle Diseases
      • 5.1.1.5. Fast Track and Orphan Drug Designations
    • 5.1.2. RESTRAINTS
      • 5.1.2.1. High Cost of Immunotherapy Treatment
      • 5.1.2.2. High Attrition Rate in the Product Development Cycle
    • 5.1.3. OPPORTUNITIES
      • 5.1.3.1. Emerging Markets
      • 5.1.3.2. Immunotherapy to Replace Chemotherapy in Cancer Treatment
    • 5.1.4. CHALLENGE
      • 5.1.4.1. Impending Patent Expiry of Top-selling Biologics

6. INDUSTRY INSIGHTS

  • 6.1. INTRODUCTION
  • 6.2. EPIDEMIOLOGY COVERAGE
    • 6.2.1. CANCER EPIDEMIOLOGY
    • 6.2.2. AUTOIMMUNE DISEASE EPIDEMIOLOGY
  • 6.3. PRICING AND REIMBURSEMENT SCENARIO
    • 6.3.1. U.S.
    • 6.3.2. U.K.
    • 6.3.3. FRANCE
    • 6.3.4. GERMANY
    • 6.3.5. OTHER EUROPEAN COUNTRIES
    • 6.3.6. JAPAN
  • 6.4. RESEARCH FUNDING & GOVERNMENT INITIATIVES
  • 6.5. PIPELINE DRUGS
    • 6.5.1. PHASE 1
    • 6.5.2. PHASE I/II
    • 6.5.3. PHASE II
    • 6.5.4. PHASE II/III
    • 6.5.5. PHASE III
    • 6.5.6. APPLICATION SUBMITTED
    • 6.5.7. PROMISING MOLECULES
  • 6.6. INDUSTRY TRENDS
  • 6.7. KEY PRODUCTS EXPECTED TO BE LAUNCHED
  • 6.8. TREATMENT PROTOCOLS AND LINE OF THERAPIES
    • 6.8.1. FIRST-LINE THERAPY
    • 6.8.2. SECOND-LINE THERAPY
    • 6.8.3. OTHER TREATMENTS
  • 6.9. BURNING ISSUES

7. IMMUNOTHERAPY DRUGS MARKET, BY TYPE OF DRUG

  • 7.1. INTRODUCTION
  • 7.2. MONOCLONAL ANTIBODIES
  • 7.3. ADULT VACCINES
    • 7.3.1. PREVENTIVE VACCINES
    • 7.3.2. THERAPEUTIC VACCINES
  • 7.4. CHECKPOINT INHIBITORS
  • 7.5. INTERFERONS ALPHA & BETA
  • 7.6. INTERLEUKINS
  • 7.7. OTHER DRUGS

8. IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA

  • 8.1. INTRODUCTION
  • 8.2. CANCER
  • 8.3. AUTOIMMUNE AND INFLAMMATORY DISEASES
  • 8.4. INFECTIOUS DISEASES
  • 8.5. OTHER THERAPY AREAS

9. IMMUNOTHERAPY DRUGS MARKET, BY END USER

  • 9.1. INTRODUCTION
  • 9.2. HOSPITALS
  • 9.3. CLINICS
  • 9.4. OTHER END USERS

10. IMMUNOTHERAPY DRUGS MARKET, BY REGION

  • 10.1. INTRODUCTION
  • 10.2. NORTH AMERICA
    • 10.2.1. U.S.
    • 10.2.2. CANADA
  • 10.3. EUROPE
    • 10.3.1. GERMANY
    • 10.3.2. U.K.
    • 10.3.3. FRANCE
    • 10.3.4. ITALY
    • 10.3.5. SPAIN
  • 10.4. ASIA-PACIFIC
    • 10.4.1. JAPAN
    • 10.4.2. CHINA
    • 10.4.3. INDIA
  • 10.5. REST OF THE WORLD (ROW)

11. COMPETITIVE LANDSCAPE

  • 11.1. INTRODUCTION
  • 11.2. STRATEGIC ANALYSIS
  • 11.3. MARKET SHARE ANALYSIS
  • 11.4. COMPETITIVE SITUATION AND TRENDS
    • 11.4.1. REGULATORY APPROVALS
    • 11.4.2. COLLABORATIONS
    • 11.4.3. AGREEMENTS
    • 11.4.4. ACQUISITIONS
    • 11.4.5. EXPANSIONS

12. COMPANY PROFILES (Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*

  • 12.1. INTRODUCTION
  • 12.2. F. HOFFMANN-LA ROCHE AG
  • 12.3. MERCK & CO., INC.
  • 12.4. NOVARTIS INTERNATIONAL AG
  • 12.5. JOHNSON & JOHNSON (A PARENT COMPANY OF JANSSEN BIOTECH, INC.)
  • 12.6. GLAXOSMITHKLINE PLC
  • 12.7. AMGEN INC.
  • 12.8. ABBVIE
  • 12.9. ASTRAZENECA
  • 12.10. BRISTOL-MYERS SQUIBB
  • 12.11. ELI LILLY AND COMPANY

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.

13. APPENDIX

  • 13.1. INSIGHTS OF INDUSTRY EXPERTS
  • 13.2. DISCUSSION GUIDE
  • 13.3. OTHER DEVELOPMENTS
  • 13.4. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.5. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 13.6. AVAILABLE CUSTOMIZATIONS
  • 13.7. RELATED REPORTS
  • 13.8. AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1: IMMUNOTHERAPY DRUGS MARKET SUMMARY
  • TABLE 2: COMPARISON OF COST (BRANDED VS BIOSIMILAR VERSION)
  • TABLE 3: CANCER: ESTIMATED INCIDENCE, MORTALITY IN MEN (2015)
  • TABLE 4: CANCER: ESTIMATED INCIDENCE, MORTALITY IN WOMEN (2015)
  • TABLE 5: GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG, 2014-2021 (USD BILLION)
  • TABLE 6: GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 7: NORTH AMERICA: MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 8: GLOBAL ADULT VACCINES MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 9: GLOBAL ADULT VACCINES MARKET SIZE, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 10: NORTH AMERICA: ADULT VACCINES MARKET SIZE, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 11: GLOBAL PREVENTIVE VACCINES MARKET SIZE, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 12: NORTH AMERICA: PREVENTIVE VACCINES MARKET SIZE, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 13: GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 14: NORTH AMERICA: THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 15: GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 16: NORTH AMERICA: CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 17: GLOBAL INTERFERONS ALPHA & BETA MARKET SIZE, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 18: NORTH AMERICA: INTERFERONS ALPHA & BETA MARKET SIZE, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 19: GLOBAL OTHER DRUGS MARKET SIZE, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 20: NORTH AMERICA: OTHER DRUGS MARKET SIZE, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 21: GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY AREA, 2014-2021 (USD BILLION)
  • TABLE 22: GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE FOR CANCER, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 23: GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE FOR CANCER, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 24: NORTH AMERICA: GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE FOR CANCER, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 25: GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE FOR SOLID TUMORS, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 26: NORTH AMERICA: GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE FOR SOLID TUMORS, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 27: GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE FOR MALIGNANT TUMORS, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 28: NORTH AMERICA: GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE FOR MALIGNANT TUMORS, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 29: GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE FOR AUTOIMMUNE AND INFLAMMATORY DISEASES, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 30: NORTH AMERICA: GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE FOR AUTOIMMUNE AND INFLAMMATORY DISEASES, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 31: GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE FOR INFECTIOUS DISEASES, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 32: NORTH AMERICA: GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE FOR INFECTIOUS DISEASES, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 33: GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE FOR OTHER THERAPY AREAS, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 34: NORTH AMERICA: GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE FOR OTHER THERAPY AREAS, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 35: GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2014-2021 (USD BILLION)
  • TABLE 36: GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE FOR HOSPITALS, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 37: NORTH AMERICA: GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE FOR HOSPITALS, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 38: GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE FOR CLINICS, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 39: NORTH AMERICA: GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE FOR CLINICS, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 40: GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE FOR OTHER END USERS, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 41: NORTH AMERICA: GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE FOR OTHER END USERS, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 42: GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 43: NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2014-2021 (USD BILLION)
  • TABLE 44: NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG, 2014-2021 (USD BILLION)
  • TABLE 45: NORTH AMERICA: ADULT VACCINES MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 46: NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY AREA, 2014-2021 (USD BILLION)
  • TABLE 47: NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET SIZE FOR CANCER, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 48: NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2014-2021 (USD BILLION)
  • TABLE 49: U.S.: IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG, 2014-2021 (USD BILLION)
  • TABLE 50: U.S.: ADULT VACCINES MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 51: THE U.S.: IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY AREA, 2014-2021 (USD BILLION)
  • TABLE 52: U.S.: IMMUNOTHERAPY DRUGS MARKET SIZE FOR CANCER, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 53: THE U.S.: IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2014-2021 (USD BILLION)
  • TABLE 54: CANADA: IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG, 2014-2021 (USD BILLION)
  • TABLE 55: CANADA: ADULT VACCINES MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 56: CANADA: IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY AREA, 2014-2021 (USD BILLION)
  • TABLE 57: CANADA: IMMUNOTHERAPY DRUGS MARKET SIZE FOR CANCER, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 58: CANADA: IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2014-2021 (USD BILLION)
  • TABLE 59: EUROPE: IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG, 2014-2021 (USD BILLION)
  • TABLE 60: EUROPE: ADULT VACCINES MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 61: EUROPE: IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY AREA, 2014-2021 (USD BILLION)
  • TABLE 62: EUROPE: IMMUNOTHERAPY DRUGS MARKET SIZE FOR CANCER, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 63: EUROPE: IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2014-2021 (USD BILLION)
  • TABLE 64: APAC.: IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG, 2014-2021 (USD BILLION)
  • TABLE 65: APAC: ADULT VACCINES MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 66: APAC: IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY AREA, 2014-2021 (USD BILLION)
  • TABLE 67: APAC: IMMUNOTHERAPY DRUGS MARKET SIZE FOR CANCER, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 68: APAC: IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2014-2021 (USD BILLION)
  • TABLE 69: ROW: IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG, 2014-2021 (USD BILLION)
  • TABLE 70: ROW: ADULT VACCINES MARKET SIZE, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 71: ROW: IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY AREA, 2014-2021 (USD BILLION)
  • TABLE 72: ROW: IMMUNOTHERAPY DRUGS MARKET SIZE FOR CANCER, BY TYPE, 2014-2021 (USD BILLION)
  • TABLE 73: ROW: IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2014-2021 (USD BILLION)
  • TABLE 74: MARKET DEVELOPMENTS, 2013-2016
  • TABLE 75: APPROVALS, 2013-2016
  • TABLE 76: COLLABORATIONS, 2013-2016
  • TABLE 77: AGREEMENTS, 2013-2016
  • TABLE 78: ACQUISITIONS, 2013-2016
  • TABLE 79: EXPANSIONS, 2013-2016

LIST OF FIGURES

  • FIGURE 1: RESEARCH DESIGN
  • FIGURE 2: MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
  • FIGURE 3: MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 4: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 5: DATA TRIANGULATION METHODOLOGY
  • FIGURE 6: IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG, 2016 VS. 2021 (USD BILLION)
  • FIGURE 7: IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY AREA, 2016 VS. 2021 (USD BILLION)
  • FIGURE 8: IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2016 VS. 2021 (USD BILLION)
  • FIGURE 9: IMMUNOTHERAPY DRUGS MARKET, BY REGION, 2016
  • FIGURE 10: IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION, 2016 VS. 2021 (USD BILLION)
  • FIGURE 11: INCREASING ADOPTION OF TARGET THERAPY OVER TRADITIONAL THERAPY TO DRIVE MARKET GROWTH
  • FIGURE 12: CANCER TO COMMAND THE LARGEST MARKET SHARE IN 2016
  • FIGURE 13: ASIA TO REGISTER HIGHEST GROWTH DURING THE FORECAST PERIOD
  • FIGURE 14: CHECKPOINT INHIBITORS EXPECTED TO BE THE FASTEST-GROWING SEGMENT
  • FIGURE 15: ASIA PRESENTS LUCRATIVE GROWTH OPPORTUNITIES IN THE IMMUNOTHERAPY DRUGS MARKET
  • FIGURE 16: INCREASING ADOPTION OF TARGETED THERAPY OVER TRADITIONAL THERAPY WILL DRIVE THE IMMUNOTHERAPY DRUGS MARKET
  • FIGURE 17: RISE IN COSTS OF CANCER IMMUNOTHERAPY DRUGS
  • FIGURE 18: PERCENTAGE OF ADULT POPULATION DIAGNOSED WITH AUTOIMMUNE DISEASES (OCTOBER 2016)
  • FIGURE 19: CANCER RESEARCH FUNDING IN 2014
  • FIGURE 20: CLINICAL PHASES OF PRODUCTS TO BE LAUNCHED
  • FIGURE 21: MONOCLONAL ANTIBODIES SEGMENT TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2016
  • FIGURE 22: PREVENTIVE VACCINES TO ACCOUNT FOR THE LARGEST SHARE IN 2016
  • FIGURE 23: GLOBAL INTERLEUKINS MARKET SIZE, 2016-2021 (USD BILLION)
  • FIGURE 24: CANCER ACCOUNT FOR THE LARGEST MARKET SHARE IN 2016
  • FIGURE 25: HOSPITALS TO DOMINATE THE IMMUNOTHERAPY DRUGS MARKET, BY END USER, DURING 2016-2021
  • FIGURE 26: GEOGRAPHIC SNAPSHOT: ASIA-PACIFIC, THE FASTEST-GROWING REGION IN 2016-2021
  • FIGURE 27: CHECKPOINT INHIBITORS SEGMENT TO WITNESS HIGH GROWTH IN THE NORTH AMERICAN AND ASIA-PACIFIC MARKETS
  • FIGURE 28: NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET SNAPSHOT
  • FIGURE 29: U.S. TO DOMINATE THE NORTH AMERICAN IMMUNOTHERAPY DRUGS MARKET
  • FIGURE 30: EUROPE: IMMUNOTHERAPY DRUGS MARKET SNAPSHOT
  • FIGURE 31: APAC: IMMUNOTHERAPY DRUGS MARKET SNAPSHOT
  • FIGURE 32: KEY DEVELOPMENTS IN THE IMMUNOTHERAPY DRUGS MARKET, 2013-2016
  • FIGURE 33: IMMUNOTHERAPY DRUGS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2015
  • FIGURE 34: GEOGRAPHIC REVENUE MIX OF THE TOP FIVE MARKET PLAYERS
  • FIGURE 35: F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
  • FIGURE 36: MERCK & CO., INC.: COMPANY SNAPSHOT
  • FIGURE 37: NOVARTIS INTERNATIONAL AG: COMPANY SNAPSHOT
  • FIGURE 38: JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • FIGURE 39: GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • FIGURE 40: AMGEN INC.: COMPANY SNAPSHOT
  • FIGURE 41: ABBVIE: COMPANY SNAPSHOT
  • FIGURE 42: ASTRAZENECA: COMPANY SNAPSHOT
  • FIGURE 43: BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
  • FIGURE 44: ELI LILLY AND COMPANY: COMPANY SNAPSHOT
Back to Top